Abstract: Screening human subjects for vector-borne disease is provided and carried out using thymidine kinase 1 alone or in combination with c-reactive protein as biomarkers which are measured in a blood sample, and the measurements are used to compute an index that allows a practitioner to compare results from different subjects and between different populations of subjects, and the screening for vector-borne disease can also be used on subjects that are undergoing treatment to monitor the progress of an infection and the results of the treatment.

Abstract: Canine subjects are screened for vector-borne diseases using Thymidine kinase (TK1) activity level alone or in conjunction with c-reactive protein (CRP) as biomarkers in the blood serum. While the canine subject may or may not display health symptoms indicative specifically of a vector-borne disease, the activity level of TK1 or in conjunction with the concentration of CRP are combined in a novel method that provides a practitioner the means of determining whether the subjects has a high probability of being affected by a vector-borne disease.

Abstract: The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale.

Abstract: The invention provides a method and apparatus for detecting cancer using the measurement of acute-phase proteins (APPs) and the measurement of thymidine kinase activity level in body fluids. An index is calculated based on the measured data and compared with a pre-established reference that allows a practitioner to determine a high probability that a patient is a carrier of cancer.

Abstract: The invention provides a method and system for developing and using diagnoses of lymphosarcoma in feline subjects using thymidine kinase (TK) and haptoglobin (HP) as biomarkers. The invention provides a method for obtaining the level of each biomarker and computing an index for a feline subject. The invention provides predefined index ranges to which the index value may be matched in order to determine whether the subject has a high probability of being affected by lymphosarcoma, even when the subject shows apparent symptoms that may be common with inflammatory bowel disease.

Abstract: The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using Thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale.

Abstract: The invention provides a method and apparatus for detecting cancer using the measurement of acute-phase proteins (APPs) and the measurement of thymidine kinase activiy level in body fluids. An index is calculated based on the measured data and compared with a pre-established reference that allows a pratitioner to determine a high probabilty that a patient is a carrier of cancer.

Abstract: The invention provides a method and a system for diagnosing lymphoma in cats. The system allows a care giver to measure the enzymatic activity of thymidine kinase in a blood sample. The invention teaches that when the enzymatic activity of thymidine kinase in the blood stream of a cat is above 15.5 Units per liter, the cat has a high probability of having lymphoma. The invention allows for initial diagnosis, follow up after treatment for lymphoma and/or monitoring for example in breeds that prone to have lymphoma.

Abstract: The invention provides a method and a system for diagnosing lymphoma in cats. The system allows a care giver to measure the enzymatic activity of thymidine kinase in a blood sample. The invention teaches that when the enzymatic activity of thymidine kinase in the blood stream of a cat is above 15.5 Units per liter, the cat has a high probability of having lymphoma. The invention allows for initial diagnosis, follow up after treatment for lymphoma and/or monitoring for example in breeds that prone to have lymphoma.

Abstract: The invention provides a method and system for developing and using diagnoses of lymphosarcoma in feline subjects using Thymidine kinase (TK) and haptoglobin (HP) as biomarkers. The invention provides a method for obtaining the level of each biomarker and computing an index for a feline subject. The invention provides predefined index ranges to which the index value may be matched in order to determine whether the subject has a high probability of being affected by lymphosarcoma, even when the subject shows apparent symptoms that may be common with inflammatory bowel disease.

Abstract: The invention provides a method and system for developing and using diagnoses of one or more underlying health affections in humans or an animal specie using a plurality of biomarkers. A target one or more affections are defined and a set of biomarkers is selected. An index is computed based on the measured levels of the biomarkers. The biomarkers levels are discretized, and each discrete value is multiplied by a corresponding coefficient. The index scale is divided into ranges that are matched with health statuses. A subject's health affection status is subsequently determined by measuring the level of each biomarker in the set, computing the index and matching the index value to the predefined index scale.

Abstract: The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using Thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale.

Abstract: The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/mL or greater.

Abstract: The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/mL or greater.